Expression of type 5 phosphodiesterase (PDE5), a cGMP-specific hydrolytic enzyme, is frequently altered in human cancer, but its specific role in tumorigenesis remains controversial. Herein, by analyzing a cohort of 69 patients affected by glioblastoma multiforme (GBM) who underwent chemo- and radiotherapy after surgical resection of the tumor, we found that PDE5 was strongly expressed in cancer cells in about 50% of the patients. Retrospective analysis indicated that high PDE5 expression in GBM cells significantly correlated with longer overall survival of patients. Furthermore, silencing of endogenous PDE5 by short hairpin lentiviral transduction (sh-PDE5) in the T98G GBM cell line induced activation of an invasive phenotype. Similarly, pharmacological inhibition of PDE5 activity strongly enhanced cell motility and invasiveness in T98G cells. This invasive phenotype was accompanied by increased secretion of metallo-proteinase 2 (MMP-2) and activation of protein kinase G (PKG). Moreover, PDE5 silencing markedly enhanced DNA damage repair and cell survival following irradiation. The enhanced radio-resistance of sh-PDE5 GBM cells was mediated by an increase of poly(ADP-ribosyl)ation (PARylation) of cellular proteins and could be counteracted by poly(ADP-ribose) polymerase (PARP) inhibitors. Conversely, PDE5 overexpression in PDE5-negative U87G cells significantly reduced MMP-2 secretion, inhibited their invasive potential and interfered with DNA damage repair and cell survival following irradiation. These studies identify PDE5 as a favorable prognostic marker for GBM, which negatively affects cell invasiveness and survival to ionizing radiation. Moreover, our work highlights the therapeutic potential of targeting PKG and/or PARP activity in this currently incurable subset of brain cancers.

Cesarini, V., Martini, M., Ricci Vitiani, L., Luca Gravina, G., Di Agostino, S., Graziani, G., et al. (2017). Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. ONCOTARGET [10.18632/oncotarget.14656].

Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome

CESARINI, VALERIANA;GRAZIANI, GRAZIA;ROSSI, PELLEGRINO;JANNINI, EMMANUELE ANGELO FRANCESCO;DOLCI IANNINI, SUSANNA
2017-01-14

Abstract

Expression of type 5 phosphodiesterase (PDE5), a cGMP-specific hydrolytic enzyme, is frequently altered in human cancer, but its specific role in tumorigenesis remains controversial. Herein, by analyzing a cohort of 69 patients affected by glioblastoma multiforme (GBM) who underwent chemo- and radiotherapy after surgical resection of the tumor, we found that PDE5 was strongly expressed in cancer cells in about 50% of the patients. Retrospective analysis indicated that high PDE5 expression in GBM cells significantly correlated with longer overall survival of patients. Furthermore, silencing of endogenous PDE5 by short hairpin lentiviral transduction (sh-PDE5) in the T98G GBM cell line induced activation of an invasive phenotype. Similarly, pharmacological inhibition of PDE5 activity strongly enhanced cell motility and invasiveness in T98G cells. This invasive phenotype was accompanied by increased secretion of metallo-proteinase 2 (MMP-2) and activation of protein kinase G (PKG). Moreover, PDE5 silencing markedly enhanced DNA damage repair and cell survival following irradiation. The enhanced radio-resistance of sh-PDE5 GBM cells was mediated by an increase of poly(ADP-ribosyl)ation (PARylation) of cellular proteins and could be counteracted by poly(ADP-ribose) polymerase (PARP) inhibitors. Conversely, PDE5 overexpression in PDE5-negative U87G cells significantly reduced MMP-2 secretion, inhibited their invasive potential and interfered with DNA damage repair and cell survival following irradiation. These studies identify PDE5 as a favorable prognostic marker for GBM, which negatively affects cell invasiveness and survival to ionizing radiation. Moreover, our work highlights the therapeutic potential of targeting PKG and/or PARP activity in this currently incurable subset of brain cancers.
Online ahead of print
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/16
English
MMP2; MYPT; PARP; PDE5; glioblastoma
Cesarini, V., Martini, M., Ricci Vitiani, L., Luca Gravina, G., Di Agostino, S., Graziani, G., et al. (2017). Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. ONCOTARGET [10.18632/oncotarget.14656].
Cesarini, V; Martini, M; Ricci Vitiani, L; Luca Gravina, G; Di Agostino, S; Graziani, G; Giorgio D'Alessandris, Q; Pallini, R; Larocca, L; Rossi, P; Jannini, Eaf; DOLCI IANNINI, S
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Cesarini Oncotarget 2017.pdf

accesso aperto

Descrizione: Articolo principale
Licenza: Copyright dell'editore
Dimensione 9.35 MB
Formato Adobe PDF
9.35 MB Adobe PDF Visualizza/Apri
Cesarini Oncotarget 2017 - Supplemental Information.pdf

accesso aperto

Descrizione: Materiale supplementare
Licenza: Copyright dell'editore
Dimensione 2.56 MB
Formato Adobe PDF
2.56 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/170935
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 19
social impact